Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973951 | 0.96 | HTR6 (0.40) | HTR6 | |
| SCHEMBL1829431 | 0.90 | HTR6 (0.44) | HTR6 | |
| SCHEMBL8717579 | 0.89 | HTR6 (0.36) | HTR6 | |
| SCHEMBL3011186 | 0.88 | HTR6 (0.38) | HTR6 | |
| SCHEMBL3959219 | 0.88 | HTR6 (0.38) | HTR6 | |
| SCHEMBL236429 | 0.88 | HTR6 (0.36) | HTR6 | |
| SCHEMBL1647530 | 0.79 | HTR6 (0.36) | HTR6 | |
| SCHEMBL139587 | 0.79 | HTR6 (0.41) | HTR6 | |
| SCHEMBL1427870 | 0.79 | HTR6 (0.36) | HTR6 | |
| SCHEMBL6274716 | 0.78 | HTR6 (0.37) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101648946-A | Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives | IL YANG PHARM CO LTD KR | 2010-02-17 | — | — | CN | claimed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | claimed |
| CN-113272272-B | RIP1 inhibitors | 圣瑞诺有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-7790734-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-7495021-B2 | Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-20070293487-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | SOCIET DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-12-20 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-0019172-A1 | 6-Substituted 11-alkylene-morphantridines, process for preparing them and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | HTR6 927/4885 |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HTR6 2321/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HTR6 1693/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | HTR6 2656/4885 |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | HTR6 1206/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | HTR6 927/4885 |
| US-20070293487-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | CDC25C, CDC25A, CDC25B | HTR6 4157/4885 |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | POLRMT, MAVS, DHX15 | HTR6 1599/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | HTR6 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.